Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Sales of Investments

Cash received from selling or redeeming investments.

Nuvation Bio Inc.NYSE: NUVB

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments declines year over year

Q2 FY2026 sales of investments of $73.94M fell 45.9% year over year, ahead of the -130.9% change in trailing-twelve-month sales of investments. Sequentially, it rose 91.8% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Sales of investments amounted to 734.9% of revenue in FY2025, down 4981.8 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -45.9% holds above the trailing-twelve-month pace of -130.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$73.94M+91.8% QoQ
Last fiscal yearDec 2025
$462.29M+2.7% YoY
LTMJun 2026
-$139.19M-130.9% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.9%——
1 year+2.7%——
3-year CAGR-7.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
462.29M USD
Year-over-year change
+2.7%
4-year CAGR
+31.4%

Sales of Investments vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's LTM Jun 2026 sales of investments of $139.19M is the 8th largest of the 11 companies compared; the peer median is $494.06M.
  • Its year-over-year change of -130.9% is the lowest of 10, against a peer median of -1.6%.
  • Sales of investments amounts to 81.9% of revenue for NUVB, versus a peer median of 545.5%.
NUVB Competitors Peer median
Sales of Investments for NUVB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$765.04M +47.0%+117.2%—
VRDNViridian Therapeutics, Inc.LTM Jun 2026$556.71M -1.6%+70.7%782.7%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$540.38M +5.6%+2.1%173.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$502.67M -21.3%+28.6%448811.6%
JANXJanux Therapeutics, Inc.LTM Mar 2026$495.32M +176.4%+4.1%2291.8%
VERAVera Therapeutics, Inc.LTM Jun 2026$492.8M +18.2%+86.5%—
ABCLAbCellera Biologics Inc.LTM Sep 2026$249.02M -57.5%-0.3%367.0%
NUVBNuvation Bio Inc.LTM Jun 2026$139.19M -130.9%-7.5%81.9%
QUREuniQure N.V.LTM Mar 2026$98.7M -74.3%—545.5%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$11.04M -102.4%+29.6%—
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding NUVB) $494.06M-1.6%+29.1%545.5%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Depreciation & Amortization184K199K222K683K1.74M
Deferred Income Tax00000
Stock-Based Compensation9.27M16.29M19.51M32.28M35.89M
Change in Working Capital4.79M(3.45M)540K(12.51M)(11.98M)
Accounts Receivables(1.95M)554K(1.22M)(12.59M)(3.07M)
Inventory0000(11.41M)
Accounts Payables1.86M(1.79M)70K(1.65M)3.13M
Other Working Capital4.88M(2.22M)1.69M1.74M(630K)
Other Non-Cash Items4.41M(4.95M)(12.47M)417.08M5.55M
Operating Cash Flow(68.19M)(96.11M)(68M)(130.41M)(173.43M)
Capital Expenditures(282K)(370K)(69K)(162K)(354K)
Acquisitions (Net)00012.43M0
Purchases of Investments(609.3M)(520.31M)(703.37M)(339.65M)(354.42M)
Sales of Investments154.91M584.12M712.35M450.08M462.29M
Other Investing Activities013K14K00
Investing Cash Flow(454.67M)63.46M8.92M122.7M99.52M
Debt Repayment000(4.55M)191.11M
Common Stock Issued0004.89M11.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities625.53M1.33M628K00
Financing Cash Flow625.53M1.33M628K331K202.54M
Effect of Forex Changes000453K(265K)
Net Change in Cash102.67M(31.32M)(58.45M)(6.93M)128.36M
Free Cash Flow(68.47M)(96.48M)(68.07M)(130.58M)(173.78M)

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.